KRAS Q61P

CI-VAR-00003572Explore in graph →NP_004976.2:p.Gln61ProNM_004985.4:c.182A>CClinVar 375966 CIViC 1103 rs121913240

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm4
KRAS Q61P	Cetuximab	Predictive	B	Supports Resistance	3	submitted	EID2805 In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC) PMID 19603018 · Loupakis et al., 2009 · Open in CIViC	civic
KRAS Q61P	Cetuximab	Predictive	C	Supports Resistance	—	submitted	EID4421 In a retrospective study of 138 metastatic irinotecan-refractory, colorectal cancer patients, patients with a KRAS codon 61 or 146 mutation (8/68) treated with cetuximab plus chemotherapy were associa… (full text at CIViC) PMID 19603018 · Loupakis et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Unmapped disease1unmapped disease
KRAS Q61P	(functional)	Functional	B	Supports Gain Of Function	3	submitted	EID7160 As seen in Figure 1, a patient with the KRAS Q61P variant had increased RAS activation, increased phosphorylation of ERK and amplification of 1q21. PMID 30201956 · Wong et al., 2018 · Open in CIViC	civic